TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS
    2.
    发明申请
    TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS 审中-公开
    在动物中治疗代谢性疾病

    公开(公告)号:US20150164856A1

    公开(公告)日:2015-06-18

    申请号:US14573352

    申请日:2014-12-17

    IPC分类号: A61K31/351 A61K38/28

    摘要: The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder in a feline animal, preferably wherein the metabolic disorder is one or more selected from the group consisting of: ketoacidosis, pre-diabetes, diabetes mellitus type 1 or type 2, insulin resistance, obesity, hyperglycemia, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, atherosclerosis, inflammation of the pancreas, neuropathy and/or Syndrome X (metabolic syndrome) and/or loss of pancreatic beta cell function and/or wherein the remission of the metabolic disorder, preferably diabetic remission, is achieved and/or maintained.

    摘要翻译: 本发明涉及用于治疗和/或预防猫科动物代谢紊乱的一种或多种SGLT2抑制剂或其药学上可接受的形式,优选其中代谢紊乱是选自以下的一种或多种:酮症酸中毒 ,前期糖尿病,1型糖尿病或2型糖尿病,胰岛素抵抗,肥胖症,高血糖症,葡萄糖耐量降低,高胰岛素血症,血脂异常,血管兴奋素血症,亚临床炎症,全身炎症,低度全身炎症,肝脂质变性,动脉粥样硬化,胰腺炎症 ,神经病和/或综合征X(代谢综合征)和/或胰腺β细胞功能丧失和/或其中代谢紊乱的缓解,优选糖尿病缓解获得和/或维持。